Login to Your Account

Series B $20M spine of Gorlin bid, Pellepharm phase III nears

By Randy Osborne
Staff Writer

Monday, July 31, 2017

Pellepharm Inc. may have come up with a "Goldilocks drug" – just enough, not too much – to treat Gorlin syndrome, its chief medical officer, Ervin Epstein, told BioWorld.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription